# COMPASS Pathways plc: financial statements, quarterly

CMPS · Nasdaq · CIK 1816590 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/cmps.md) · [Financials](/companies/cmps/financials.md) · [Filings](/companies/cmps/filings.md) · [Insiders](/companies/cmps/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/cmps/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $m | [21.5](/filings/0001628280-24-044398.md) | [27.1 d](/filings/0001628280-25-008412.md) | [24.9](/filings/0001628280-25-023426.md) | [29.1](/filings/0001816590-25-000102.md) | [32.9](/filings/0001816590-25-000150.md) | [32.1 d](/filings/0001816590-26-000020.md) | [30.9](/filings/0001816590-26-000042.md) | [30.3](/filings/0001816590-26-000058.md) | [27.3](/filings/0001816590-25-000150.md) | [29.9 d](/filings/0001816590-26-000020.md) | [26.5](/filings/0001816590-26-000042.md) | [29.2](/filings/0001816590-26-000058.md) |
| Operating income | $m | [(34.1)](/filings/0001628280-24-044398.md) | [(38.4) d](/filings/0001628280-25-008412.md) | [(38.6)](/filings/0001628280-25-023426.md) | [(43.3)](/filings/0001816590-25-000102.md) | [(47.9)](/filings/0001816590-25-000150.md) | [(48.4) d](/filings/0001816590-26-000020.md) | [(49.6)](/filings/0001816590-26-000042.md) | [(42.9)](/filings/0001816590-26-000058.md) | [(40.5)](/filings/0001816590-25-000150.md) | [(46.0) d](/filings/0001816590-26-000020.md) | [(42.9)](/filings/0001816590-26-000042.md) | [(52.4)](/filings/0001816590-26-000058.md) |
| Interest expense | $m | [1.1](/filings/0001628280-23-036170.md) | [1.1 d](/filings/0001628280-24-007787.md) | [1.1](/filings/0001628280-24-021351.md) | [1.1](/filings/0001816590-25-000102.md) | [1.1](/filings/0001816590-25-000150.md) | [1.1 d](/filings/0001816590-26-000020.md) | [1.1](/filings/0001816590-26-000042.md) | [1.2](/filings/0001816590-26-000058.md) | [1.1](/filings/0001816590-25-000150.md) | [1.1 d](/filings/0001816590-26-000020.md) | [1.5](/filings/0001816590-26-000042.md) | [1.5](/filings/0001816590-26-000058.md) |
| Income tax | $m | [0.1](/filings/0001628280-24-044398.md) | [0.4 d](/filings/0001628280-25-008412.md) | [0.2](/filings/0001628280-25-023426.md) | [0.2](/filings/0001816590-25-000102.md) | [0.2](/filings/0001816590-25-000150.md) | [1.0 d](/filings/0001816590-26-000020.md) | [0.4](/filings/0001816590-26-000042.md) | [0.1](/filings/0001816590-26-000058.md) | [(0.2)](/filings/0001816590-25-000150.md) | [(2.7) d](/filings/0001816590-26-000020.md) | [(0.0)](/filings/0001816590-26-000042.md) | [0.3](/filings/0001816590-26-000058.md) |
| Net income | $m | [(33.4)](/filings/0001628280-24-044398.md) | [(32.5) d](/filings/0001628280-25-008412.md) | [(35.2)](/filings/0001816590-25-000150.md) | [(38.1)](/filings/0001816590-25-000150.md) | [(38.5)](/filings/0001816590-25-000150.md) | [(43.3) d](/filings/0001816590-26-000020.md) | [(17.9)](/filings/0001816590-26-000058.md) | [(38.4)](/filings/0001816590-26-000058.md) | [(138)](/filings/0001816590-25-000150.md) | [(93.9) d](/filings/0001816590-26-000020.md) | [91.2](/filings/0001816590-26-000058.md) | [(254)](/filings/0001816590-26-000058.md) |
| Diluted EPS | $ per share | [(0.67)](/filings/0001628280-24-044398.md) | not reported | [(0.55)](/filings/0001628280-25-023426.md) | [(0.56)](/filings/0001816590-25-000102.md) | [(0.56)](/filings/0001816590-25-000150.md) | not reported | [(0.24)](/filings/0001816590-26-000042.md) | [(0.41)](/filings/0001816590-26-000058.md) | [(1.44)](/filings/0001816590-25-000150.md) | not reported | [(0.30)](/filings/0001816590-26-000042.md) | [(1.88)](/filings/0001816590-26-000058.md) |
| Basic EPS | $ per share | [(0.67)](/filings/0001628280-24-044398.md) | not reported | [(0.55)](/filings/0001628280-25-023426.md) | [(0.56)](/filings/0001816590-25-000102.md) | [(0.56)](/filings/0001816590-25-000150.md) | not reported | [(0.20)](/filings/0001816590-26-000042.md) | [(0.41)](/filings/0001816590-26-000058.md) | [(1.44)](/filings/0001816590-25-000150.md) | not reported | [0.71](/filings/0001816590-26-000042.md) | [(1.88)](/filings/0001816590-26-000058.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [248](/filings/0001628280-24-044398.md) | [220](/filings/0001628280-25-008412.md) | [263](/filings/0001628280-25-023426.md) | [229](/filings/0001816590-25-000102.md) | [207](/filings/0001816590-25-000150.md) | [165](/filings/0001816590-26-000020.md) | [260](/filings/0001816590-26-000042.md) | [222](/filings/0001816590-26-000058.md) | [186](/filings/0001816590-25-000150.md) | [150](/filings/0001816590-26-000058.md) | [466](/filings/0001816590-26-000042.md) | [433](/filings/0001816590-26-000058.md) |
| Current assets | $m | [285](/filings/0001628280-23-036170.md) | [261](/filings/0001628280-25-008412.md) | [296](/filings/0001628280-24-021351.md) | [265](/filings/0001628280-24-033853.md) | [234](/filings/0001628280-24-044398.md) | [201](/filings/0001816590-26-000020.md) | [305](/filings/0001628280-25-023426.md) | [276](/filings/0001816590-25-000102.md) | [242](/filings/0001816590-25-000150.md) | [191](/filings/0001816590-26-000058.md) | [511](/filings/0001816590-26-000042.md) | [476](/filings/0001816590-26-000058.md) |
| Total assets | $m | [299](/filings/0001628280-23-036170.md) | [276](/filings/0001628280-25-008412.md) | [309](/filings/0001628280-24-021351.md) | [279](/filings/0001628280-24-033853.md) | [247](/filings/0001628280-24-044398.md) | [214](/filings/0001816590-26-000020.md) | [319](/filings/0001628280-25-023426.md) | [294](/filings/0001816590-25-000102.md) | [256](/filings/0001816590-25-000150.md) | [210](/filings/0001816590-26-000058.md) | [532](/filings/0001816590-26-000042.md) | [505](/filings/0001816590-26-000058.md) |
| Current liabilities | $m | [15.4](/filings/0001628280-23-036170.md) | [19.6](/filings/0001628280-25-008412.md) | [19.4](/filings/0001628280-24-021351.md) | [22.0](/filings/0001628280-24-033853.md) | [26.2](/filings/0001628280-24-044398.md) | [34.0](/filings/0001816590-26-000020.md) | [30.0](/filings/0001628280-25-023426.md) | [31.3](/filings/0001816590-25-000102.md) | [197](/filings/0001816590-25-000150.md) | [248](/filings/0001816590-26-000058.md) | [154](/filings/0001816590-26-000042.md) | [367](/filings/0001816590-26-000058.md) |
| Total liabilities | $m | [45.8](/filings/0001628280-23-036170.md) | [50.2](/filings/0001628280-25-008412.md) | [49.8](/filings/0001628280-24-021351.md) | [52.3](/filings/0001628280-24-033853.md) | [54.3](/filings/0001628280-24-044398.md) | [59.0](/filings/0001816590-26-000020.md) | [124](/filings/0001628280-25-023426.md) | [131](/filings/0001816590-25-000102.md) | [218](/filings/0001816590-25-000150.md) | [263](/filings/0001816590-26-000058.md) | [205](/filings/0001816590-26-000042.md) | [420](/filings/0001816590-26-000058.md) |
| Long-term debt | $m | [28.4](/filings/0001628280-23-036170.md) | [28.8](/filings/0001628280-25-008412.md) | [29.1](/filings/0001628280-24-021351.md) | [29.4](/filings/0001628280-24-033853.md) | [27.6](/filings/0001628280-24-044398.md) | [24.7](/filings/0001816590-26-000020.md) | [21.6](/filings/0001628280-25-023426.md) | [23.0](/filings/0001816590-25-000102.md) | [18.6](/filings/0001816590-25-000150.md) | [14.1](/filings/0001816590-26-000058.md) | [50.5](/filings/0001816590-26-000042.md) | [50.7](/filings/0001816590-26-000058.md) |
| Current portion of debt | $m | not reported | [0.0](/filings/0001628280-25-008412.md) | not reported | not reported | [2.2](/filings/0001628280-24-044398.md) | [5.5](/filings/0001816590-26-000020.md) | [9.0](/filings/0001628280-25-023426.md) | [8.0](/filings/0001816590-25-000102.md) | [12.7](/filings/0001816590-25-000150.md) | [17.5](/filings/0001816590-26-000058.md) | [0.0](/filings/0001816590-26-000042.md) | [0.0](/filings/0001816590-26-000058.md) |
| Shareholders' equity | $m | [253](/filings/0001628280-24-044398.md) | [226](/filings/0001816590-26-000020.md) | [259](/filings/0001816590-25-000150.md) | [226](/filings/0001816590-25-000150.md) | [193](/filings/0001816590-25-000150.md) | [155](/filings/0001816590-26-000058.md) | [195](/filings/0001816590-26-000058.md) | [163](/filings/0001816590-26-000058.md) | [37.6](/filings/0001816590-25-000150.md) | [(52.8)](/filings/0001816590-26-000058.md) | [327](/filings/0001816590-26-000058.md) | [84.5](/filings/0001816590-26-000058.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt, us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent, us-gaap:DebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(17.1) d](/filings/0001628280-24-044398.md) | [(27.8) d](/filings/0001628280-25-008412.md) | [(20.8)](/filings/0001628280-25-023426.md) | [(34.4) d](/filings/0001816590-25-000102.md) | [(22.2) d](/filings/0001816590-25-000150.md) | [(41.8) d](/filings/0001816590-26-000020.md) | [(45.7)](/filings/0001816590-26-000042.md) | [(38.7) d](/filings/0001816590-26-000058.md) | [(35.1) d](/filings/0001816590-25-000150.md) | [(37.8) d](/filings/0001816590-26-000020.md) | [(47.9)](/filings/0001816590-26-000042.md) | [(40.3) d](/filings/0001816590-26-000058.md) |
| Capital expenditure | $m | [0.0 d](/filings/0001628280-24-044398.md) | [0.0 d](/filings/0001628280-25-008412.md) | [0.0](/filings/0001628280-24-021351.md) | [0.0 d](/filings/0001628280-24-033853.md) | [0.0 d](/filings/0001628280-24-044398.md) | [0.0 d](/filings/0001628280-25-008412.md) | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [42.5](/filings/0001628280-23-036170.md) | [42.7](/filings/0001628280-24-021351.md) | [45.6](/filings/0001628280-24-033853.md) | [49.6](/filings/0001628280-24-044398.md) | [64.2](/filings/0001628280-25-023426.md) | [68.4](/filings/0001816590-25-000102.md) | [68.4](/filings/0001816590-25-000150.md) | [98.6](/filings/0001816590-26-000042.md) | [93.3](/filings/0001816590-26-000058.md) | [95.3](/filings/0001816590-25-000150.md) | [130](/filings/0001816590-26-000042.md) | [135](/filings/0001816590-26-000058.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 138,476,822 at 2026-07-30, from the cover of the [10-Q filed 2026-08-05](/filings/0001816590-26-000058.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.